Two stocks in Biotechnology
Genus vs Oxford Biomedica: profit, growth, debt and price compared
Genus is stronger on 3 of 6 figures: profit margin, debt and price for its expected profit. Oxford Biomedica is stronger on 2: sales growth and price trend.
Save both stocks to your watchlist and revisit their latest fundamentals.
| GenusGNS.L | Oxford BiomedicaOXB.L | |
|---|---|---|
| Net margin | Stronger: 43.4% | −23.2% |
| Revenue growth, past year | −4.10% | Stronger: +9.00% |
| Debt to equity | Stronger: 14.0% | 273.1% |
| Forward P/E | Stronger: 18.5× | Loss |
| Dividend yield | 1.56% | — |
| Analysts | Buy · 13 | Buy · 8 |
| From its 200-day average | −7.1% | Stronger: −5.2% |
Share price over the past year
- Genus−14.3%
- Oxford Biomedica−13.2%
20 Nov 202518 Nov 2026
Genus or Oxford Biomedica: which is stronger?
- GNS.L
Which is more profitable?
Genus keeps more of each sale as profit: 43.4% against −23.2%.
- OXB.L
Which is growing its sales faster?
Oxford Biomedica is growing its sales faster: +9.00% over the past year, against −4.10%.
- GNS.L
Which has borrowed less?
Genus has borrowed less: its debt is 14.0% of what its shareholders own, against 273.1% for Oxford Biomedica.
- GNS.L
Which costs less for the profit it is expected to make?
Genus is expected to make a profit over the next year, where Oxford Biomedica is expected to make a loss.
Which pays more in dividends?
Genus pays 1.56% a year in dividends for what a share costs, where Oxford Biomedica pays none.
Which do analysts rate higher?
Analysts rate both the same: Buy.
- OXB.L
Which is in the stronger price trend?
Oxford Biomedica's price is in the stronger trend: 5.2% below its 200-day average, against 7.1% below.
What each company does
GNS.LGenus
Genus plc produces and sells animal genetics to farmers in North America, Latin America, the United Kingdom, the rest of Europe, the Middle East, Russia, Africa, and Asia.
Reports results on 25 February 2027
OXB.LOxford Biomedica
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide.
Reports results on 25 March 2027
This comparison is just the starting point.
Discover opportunities, understand companies and compare investments in one place. See how StratDeck works
Keep researching
Where next
More comparisons
Free email
Up to speed in minutes, four times a week
Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.
Early access
Become a StratDeck founding user
Use StratDeck, tell us what's missing, and help decide what we build next.
100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.